Superoxide Dismutase (SOD) has been investigated for its potential role in treating psoriasis due to its antioxidant properties. Psoriasis is a chronic inflammatory skin disease characterized by increased oxidative stress and overproduction of reactive oxygen species (ROS), which contribute to inflammation and keratinocyte proliferation. SOD is an endogenous enzyme that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide, thus reducing oxidative damage.

Several small-scale studies and preclinical experiments have indicated that SOD levels may be decreased in psoriatic lesions, and that supplementation with SOD or SOD mimetics could help reduce oxidative stress in affected tissues. For example, topical formulations containing SOD have shown some benefit in reducing inflammation and lesion severity in limited clinical contexts. However, the clinical evidence remains modest, with few large-scale randomized controlled trials. Some animal studies and early-phase human trials suggest a potential for SOD as an adjunct therapy, but results are not consistently robust or widely replicated.

In summary, there is a scientific rationale for the use of SOD in psoriasis, and limited experimental evidence suggests possible benefit. However, current clinical evidence is not strong or comprehensive enough to firmly recommend SOD as a primary treatment for psoriasis. Further well-designed clinical trials are needed to establish its efficacy and safety.